Macro
Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.
Home
tech
energy
finance
healthcare
defense
industrial
consumer
communication
utilities
real estate
raw materials
← back
healthcare · sector mood
recent 3 years
now
+0.40
Recent mood · last 3 years
bearish −1
+1 bullish
Full history since 1969-01 ▾
1969-01 → 2026-08 · 692 monthly reads
News
· healthcare
The biggest healthcare stories of the last 3 years.
Biden Administration Announces First Medicare Drug Prices, Projecting $6B in Savings
The Biden administration revealed negotiated prices for 10 high-cost Medicare drugs, projecting $6 billion in savings for the program and $1.5 billion in out-of-pocket savings for enrollees by 2026. The move, enabled by the Inflation Reduction Act, marks a shift in U.S. drug pricing policy, setting a precedent for future negotiations with major pharmaceutical companies including Merck, Eli Lilly, and Johnson & Johnson. While patient advocates applaud the effort, the industry warns of reduced innovation and ongoing legal challenges.
cnbc.com
Aug 15, 2024
Trump announces 100% tariffs on imported generic drugs starting 2028
President Trump announced via social media a plan to impose 100% tariffs on imported generic drugs starting in August 2028, escalating to 200% after one year, to force manufacturers to move production to the U.S. The proposal targets a nearly $500 billion global industry where generics account for 90% of U.S. prescriptions; India supplies over 50% of these drugs, and China provides most active pharmaceutical ingredients. Industry experts and representatives expressed skepticism, noting generic manufacturers operate on single-digit margins, making the tariffs effectively a "market-exit notice." Building domestic manufacturing takes at least four to five years, according to India's Pharmexcil chairman, suggesting the two-year tariff-free period may be insufficient. The Association for Accessible Medicines called for broader policy changes. Companies with existing U.S. production, like Amphastar and Hikma, are better positioned, while Teva and Viatris face greater exposure. It remains unclear if tariffs apply to finished drugs only or also to those using imported ingredients. New reporting highlights that generic drugmakers, unlike patented pharma giants like Johnson & Johnson and Eli Lilly, operate on thin margins due to price wars—prices can fall 70% in two years after patent expiry—making reshoring less viable. Erez Israeli, CEO of Dr. Reddy's, stated tariffs would force price increases in the U.S., and the Global Trade Research Initiative noted many Indian generics would remain cost-competitive even after 100% tariffs, with costs likely passed to patients, insurers, and providers.
cnbc.com
Jul 22, 2026
58% Chance of Fed Rate Hike in October; 3 Stocks to Buy
The Federal Reserve may raise interest rates in October, with CME Group's FedWatch tool showing a 57.7% probability of a hike at the late-October FOMC meeting, following a 44.1% chance in September. Despite the potential for rising rates to hurt many stocks, three are recommended as buys: UnitedHealth Group, which has seen a 20% year-to-date gain and a 54% earnings jump in Q2 2026; JPMorgan Chase, which benefits from higher net interest income, reporting $25.6 billion in Q2; and Chevron, which gains from elevated fuel prices tied to the Iran war and resurging inflation, with shares up over 20% in 2026.
finance.yahoo.com
Aug 09, 2026
Eli Lilly Grows 55.5% in Q1 2026; Foundayo Oral GLP-1 Cleared
Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year-over-year, beating consensus estimates, and raised full-year guidance by $2 billion. The FDA cleared Foundayo, the first any-time-of-day oral GLP-1 drug, which drove 80% new-to-class prescriptions in early launch data. Mounjaro revenue surged 125% to $8.66 billion, and Zepbound rose 80% to $4.16 billion. The company also completed a $6.3 billion Centessa acquisition and a $6.5 billion manufacturing plant investment. However, realized prices fell 13% amid volume gains, and Novo Nordisk filed a false-advertising lawsuit. 24/7 Wall St. set a $1,365.51 price target with a buy rating, citing Foundayo's potential to expand the oral obesity market globally.
247wallst.com
Jul 24, 2026
Indian Stock Markets Plunge as Global Headwinds Intensify
Indian stock markets suffered their steepest fall in 10 sessions on Wednesday, extending losses to a third consecutive day. The BSE Sensex dropped 715.06 points (0.92%) to 76,755.05, while the Nifty50 fell 191.45 points (0.79%) to 23,996.25, erasing approximately Rs 4.2-4.25 lakh crore in investor wealth. The selloff was driven by escalating US-Iran tensions—with the 11th consecutive night of US strikes targeting Iranian military infrastructure—and a sharp spike in crude oil prices, with Brent surging 3.5% to $94.20 per barrel and WTI climbing 3.8% to $87.56, raising concerns about supply disruptions through the Strait of Hormuz. Additional pressure came from US President Donald Trump's phased tariff plan on imported generic medicines, proposing zero tariffs for two years starting August 1, 2026, followed by 100% for one year and then 200%, hitting India's dominant pharma export sector. The Indian rupee weakened to 96.36 per dollar, while US Treasury yields rose. Broad-based selling hit banking, IT, auto, and pharma stocks, with foreign institutional investors likely net sellers. Analysts expect near-term volatility to persist, hinging on global crude prices and geopolitical developments.
timesofindia.indiatimes.com
Jul 22, 2026
FDA approves Eli Lilly's Zepbound for weight loss, boosting obesity drug market
The FDA approved Eli Lilly's tirzepatide, marketed as Zepbound, for chronic weight management in adults with obesity or overweight with related conditions, expanding its use beyond Type 2 diabetes treatment Mounjaro. The approval positions Eli Lilly as a major competitor to Novo Nordisk in the rapidly growing $100 billion potential obesity drug market, with Zepbound expected to launch by year-end at $1,060 per month. While the drug demonstrated up to 22.5% average weight loss in trials, market implications include ongoing challenges with insurance coverage, potential supply constraints, and safety monitoring for side effects like pancreatitis and suicidal ideation.
cnbc.com
Nov 08, 2023
Novo Nordisk briefly overtakes LVMH as Europe's most valuable company
Novo Nordisk surged past LVMH in market value, driven by strong demand for its weight-loss drugs Ozempic and Wegovy, amid positive clinical results and robust sales growth. The Danish drugmaker's market cap reached $421 billion, briefly surpassing LVMH's $421 billion, reflecting investor confidence in its healthcare innovations. This shift underscores a broader market trend favoring pharmaceutical and metabolic health advancements over luxury goods, especially as LVMH faces headwinds from weakening Chinese consumer spending.
cnbc.com
Sep 01, 2023
Baron Fund: Eli Lilly Leads $150 Billion Obesity Drug Market
Baron Health Care Fund's Q2 2026 investor letter highlighted Eli Lilly as a top performer in the obesity drug market, which it projects could exceed $150 billion. Eli Lilly's GLP-1 therapies, including the new daily oral Foundayo, gained coverage from all three major pharmacy benefit managers, reversing prior concerns about a price war with Novo Nordisk. Phase 3 data for retatrutide showed weight loss in the high-20% range at higher doses, while eloralintide demonstrated Zepbound-like efficacy. Eli Lilly closed at $1,121.36 per share on August 3, 2026, with a market cap of $1.06 trillion, up 46.40% over 52 weeks.
finance.yahoo.com
Aug 04, 2026
Eli Lilly Sets 2027 FDA Filing for Next-Gen Weight-Loss Drug Retatrutide
Eli Lilly plans to file for FDA approval of its next-generation weight-loss drug retatrutide in the first quarter of 2027. In a phase 3 trial, retatrutide achieved average weight loss of up to 28.3% over 80 weeks, surpassing results from Novo Nordisk's Wegovy and even Lilly's own Zepbound. The drug mimics three gut hormones, offering a triple-pathway approach to obesity, and is also being studied for diabetes, sleep apnea, chronic back pain, and liver disease. Lilly's second-quarter revenue rose 48% year over year to $23 billion, driven by its weight-loss portfolio, as the company aims to extend its market lead over Novo Nordisk.
fool.com
Aug 07, 2026
Obesity drugs and China deals could push 2032 pharma sales above $2T
Global pharmaceutical sales are projected to exceed $2 trillion by 2032, driven by obesity and inflammatory drugs, according to Evaluate's World Preview 2026 report. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is forecast to generate over $70 billion that year, making it the biggest drug ever, while AbbVie's Skyrizi is expected to be the second top-seller at $33 billion. The report highlights a resurgence in M&A, with Chinese assets accounting for over two-thirds of 2026 deal value. However, challenges include U.S. drug pricing pressures, a patent cliff risking $500 billion in sales, and increasing competition in popular indications.
fiercepharma.com
Jun 23, 2026
Eli Lilly Outshines Novo Nordisk as Better GLP-1 Stock
Eli Lilly outperformed Novo Nordisk in Q2 GLP-1 drug sales, with Zepbound revenue reaching $4.9 billion (up 46% YoY) versus Wegovy's ~$3 billion (up 1% YoY). Tirzepatide, marketed as Mounjaro and Zepbound, showed superior efficacy in a head-to-head study, achieving 20.2% average weight loss compared to semaglutide's 13.7% over 72 weeks. Eli Lilly also boasts a broader pipeline beyond diabetes and weight loss, including cancer drug Verzenio and Alzheimer's treatment Kisunla, while Novo Nordisk's pipeline is more limited. Despite Novo Nordisk's lower forward P/E of 13.8x versus Eli Lilly's 32.7x, Eli Lilly's faster revenue and earnings growth make it the stronger buy.
fool.com
Aug 12, 2026
Berenberg Downgrades Novo Nordisk on Wegovy Pill Upside Played Out
Novo Nordisk shares fell 2.23% after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 and ADR target to $47. Analyst Kerry Holford said the upside from the Wegovy pill that supported the previous Buy rating has already been realized, with consensus and Berenberg modeling around DKK 15 billion in Wegovy pill sales for 2026, leaving little room for surprises. While Berenberg raised its 2026 revenue estimate 2.9% to DKK 296.18 billion and EPS 10.8% to DKK 23.12, it cut 2028 revenue 2.3% to DKK 308.76 billion and EBIT 2.8% to DKK 125.05 billion on weaker CagriSema assumptions. The broker also expects Eli Lilly to capture a disproportionate share of the Medicare weight-loss market, intensifying direct-to-consumer spending in the second half.
finance.yahoo.com
Aug 12, 2026